Significant elevation of plasma matrix metalloproteinase-9 level and its ratio to matrix metalloproteinase-2 in patients with pelvic inflammatory disease

Po Hui Wang, Hsiu Ting Tsai, Yi Torng Tee, Long Yau Lin, Shun Fa Yang, Yih Shou Hsieh

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Objective: To detect the expression of plasma matrix metalloproteinase-2 (MMP-2) and MMP-9, and MMP-9:MMP-2 ratio in patients with pelvic inflammatory disease (PID). Design: A consecutive study with approximate 1:2 case-to-control ratio. Setting: University hospital. Patient(s): Forty-seven patients with PID and 80 healthy women. Intervention(s): Collected blood specimens of patients with PID before and after treatment. Main Outcome Measure(s): ELISA and gelatin zymography were used to measure the expression of plasma MMP-2 and MMP-9. Result(s): The level of plasma MMP-9 or MMP-9:MMP-2 ratio was elevated in patients with PID compared with healthy controls and decreased significantly after treatment. The activity of MMP-9, but not MMP-2, tended to be higher in 47 patients with PID before the treatment compared with that after the treatment. Pretreatment plasma MMP-9 or MMP-9:MMP-2 ratio was significantly correlated with white blood cell (WBC) and neutrophil counts. As prediction markers for PID, the sensitivities of MMP-9 and MMP-9:MMP-2 ratio were 76.6% and 76.6%, whereas the negative predictive values were 82.5% and 83.3%. Conclusion(s): Level of plasma MMP-9 and MMP-9:MMP-2 ratio may act as prediction markers for PID. In patients with PID, 80% have a plasma MMP-9 level higher than 115 ng/mL or a MMP-9:MMP-2 ratio higher than 2.15.

Original languageEnglish
Pages (from-to)1679-1684
Number of pages6
JournalFertility and Sterility
Volume92
Issue number5
DOIs
Publication statusPublished - Nov 2009
Externally publishedYes

Fingerprint

Pelvic Inflammatory Disease
Matrix Metalloproteinase 2
Matrix Metalloproteinase 9
Matrix Metalloproteinases
Gelatin
Therapeutics
Leukocyte Count
Neutrophils
Enzyme-Linked Immunosorbent Assay
Outcome Assessment (Health Care)

Keywords

  • Matrix metalloproteinase-9
  • MMP-9:MMP-2 ratio
  • pelvic inflammatory disease

ASJC Scopus subject areas

  • Obstetrics and Gynaecology
  • Reproductive Medicine

Cite this

Significant elevation of plasma matrix metalloproteinase-9 level and its ratio to matrix metalloproteinase-2 in patients with pelvic inflammatory disease. / Wang, Po Hui; Tsai, Hsiu Ting; Tee, Yi Torng; Lin, Long Yau; Yang, Shun Fa; Hsieh, Yih Shou.

In: Fertility and Sterility, Vol. 92, No. 5, 11.2009, p. 1679-1684.

Research output: Contribution to journalArticle

@article{b33c3de37d6d4b81aeb1ff2dd93a960f,
title = "Significant elevation of plasma matrix metalloproteinase-9 level and its ratio to matrix metalloproteinase-2 in patients with pelvic inflammatory disease",
abstract = "Objective: To detect the expression of plasma matrix metalloproteinase-2 (MMP-2) and MMP-9, and MMP-9:MMP-2 ratio in patients with pelvic inflammatory disease (PID). Design: A consecutive study with approximate 1:2 case-to-control ratio. Setting: University hospital. Patient(s): Forty-seven patients with PID and 80 healthy women. Intervention(s): Collected blood specimens of patients with PID before and after treatment. Main Outcome Measure(s): ELISA and gelatin zymography were used to measure the expression of plasma MMP-2 and MMP-9. Result(s): The level of plasma MMP-9 or MMP-9:MMP-2 ratio was elevated in patients with PID compared with healthy controls and decreased significantly after treatment. The activity of MMP-9, but not MMP-2, tended to be higher in 47 patients with PID before the treatment compared with that after the treatment. Pretreatment plasma MMP-9 or MMP-9:MMP-2 ratio was significantly correlated with white blood cell (WBC) and neutrophil counts. As prediction markers for PID, the sensitivities of MMP-9 and MMP-9:MMP-2 ratio were 76.6{\%} and 76.6{\%}, whereas the negative predictive values were 82.5{\%} and 83.3{\%}. Conclusion(s): Level of plasma MMP-9 and MMP-9:MMP-2 ratio may act as prediction markers for PID. In patients with PID, 80{\%} have a plasma MMP-9 level higher than 115 ng/mL or a MMP-9:MMP-2 ratio higher than 2.15.",
keywords = "Matrix metalloproteinase-9, MMP-9:MMP-2 ratio, pelvic inflammatory disease",
author = "Wang, {Po Hui} and Tsai, {Hsiu Ting} and Tee, {Yi Torng} and Lin, {Long Yau} and Yang, {Shun Fa} and Hsieh, {Yih Shou}",
year = "2009",
month = "11",
doi = "10.1016/j.fertnstert.2008.08.113",
language = "English",
volume = "92",
pages = "1679--1684",
journal = "Fertility and Sterility",
issn = "0015-0282",
publisher = "Elsevier",
number = "5",

}

TY - JOUR

T1 - Significant elevation of plasma matrix metalloproteinase-9 level and its ratio to matrix metalloproteinase-2 in patients with pelvic inflammatory disease

AU - Wang, Po Hui

AU - Tsai, Hsiu Ting

AU - Tee, Yi Torng

AU - Lin, Long Yau

AU - Yang, Shun Fa

AU - Hsieh, Yih Shou

PY - 2009/11

Y1 - 2009/11

N2 - Objective: To detect the expression of plasma matrix metalloproteinase-2 (MMP-2) and MMP-9, and MMP-9:MMP-2 ratio in patients with pelvic inflammatory disease (PID). Design: A consecutive study with approximate 1:2 case-to-control ratio. Setting: University hospital. Patient(s): Forty-seven patients with PID and 80 healthy women. Intervention(s): Collected blood specimens of patients with PID before and after treatment. Main Outcome Measure(s): ELISA and gelatin zymography were used to measure the expression of plasma MMP-2 and MMP-9. Result(s): The level of plasma MMP-9 or MMP-9:MMP-2 ratio was elevated in patients with PID compared with healthy controls and decreased significantly after treatment. The activity of MMP-9, but not MMP-2, tended to be higher in 47 patients with PID before the treatment compared with that after the treatment. Pretreatment plasma MMP-9 or MMP-9:MMP-2 ratio was significantly correlated with white blood cell (WBC) and neutrophil counts. As prediction markers for PID, the sensitivities of MMP-9 and MMP-9:MMP-2 ratio were 76.6% and 76.6%, whereas the negative predictive values were 82.5% and 83.3%. Conclusion(s): Level of plasma MMP-9 and MMP-9:MMP-2 ratio may act as prediction markers for PID. In patients with PID, 80% have a plasma MMP-9 level higher than 115 ng/mL or a MMP-9:MMP-2 ratio higher than 2.15.

AB - Objective: To detect the expression of plasma matrix metalloproteinase-2 (MMP-2) and MMP-9, and MMP-9:MMP-2 ratio in patients with pelvic inflammatory disease (PID). Design: A consecutive study with approximate 1:2 case-to-control ratio. Setting: University hospital. Patient(s): Forty-seven patients with PID and 80 healthy women. Intervention(s): Collected blood specimens of patients with PID before and after treatment. Main Outcome Measure(s): ELISA and gelatin zymography were used to measure the expression of plasma MMP-2 and MMP-9. Result(s): The level of plasma MMP-9 or MMP-9:MMP-2 ratio was elevated in patients with PID compared with healthy controls and decreased significantly after treatment. The activity of MMP-9, but not MMP-2, tended to be higher in 47 patients with PID before the treatment compared with that after the treatment. Pretreatment plasma MMP-9 or MMP-9:MMP-2 ratio was significantly correlated with white blood cell (WBC) and neutrophil counts. As prediction markers for PID, the sensitivities of MMP-9 and MMP-9:MMP-2 ratio were 76.6% and 76.6%, whereas the negative predictive values were 82.5% and 83.3%. Conclusion(s): Level of plasma MMP-9 and MMP-9:MMP-2 ratio may act as prediction markers for PID. In patients with PID, 80% have a plasma MMP-9 level higher than 115 ng/mL or a MMP-9:MMP-2 ratio higher than 2.15.

KW - Matrix metalloproteinase-9

KW - MMP-9:MMP-2 ratio

KW - pelvic inflammatory disease

UR - http://www.scopus.com/inward/record.url?scp=70350574842&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70350574842&partnerID=8YFLogxK

U2 - 10.1016/j.fertnstert.2008.08.113

DO - 10.1016/j.fertnstert.2008.08.113

M3 - Article

VL - 92

SP - 1679

EP - 1684

JO - Fertility and Sterility

JF - Fertility and Sterility

SN - 0015-0282

IS - 5

ER -